MX2016013963A - Metodos mejorados para la elaboracion de terapias celulares adoptivas. - Google Patents

Metodos mejorados para la elaboracion de terapias celulares adoptivas.

Info

Publication number
MX2016013963A
MX2016013963A MX2016013963A MX2016013963A MX2016013963A MX 2016013963 A MX2016013963 A MX 2016013963A MX 2016013963 A MX2016013963 A MX 2016013963A MX 2016013963 A MX2016013963 A MX 2016013963A MX 2016013963 A MX2016013963 A MX 2016013963A
Authority
MX
Mexico
Prior art keywords
adoptive cell
cell therapies
improved methods
manufacturing
manufacturing adoptive
Prior art date
Application number
MX2016013963A
Other languages
English (en)
Other versions
MX370018B (es
Inventor
Morgan Richard
friedman Kevin
MAIER Dawn
Original Assignee
Bluebird Bio Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=54333268&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX2016013963(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Bluebird Bio Inc filed Critical Bluebird Bio Inc
Publication of MX2016013963A publication Critical patent/MX2016013963A/es
Publication of MX370018B publication Critical patent/MX370018B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/461—Cellular immunotherapy characterised by the cell type used
    • A61K39/4611—T-cells, e.g. tumor infiltrating lymphocytes [TIL], lymphokine-activated killer cells [LAK] or regulatory T cells [Treg]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/463—Cellular immunotherapy characterised by recombinant expression
    • A61K39/4631—Chimeric Antigen Receptors [CAR]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/4643—Vertebrate antigens
    • A61K39/4644—Cancer antigens
    • A61K39/464402—Receptors, cell surface antigens or cell surface determinants
    • A61K39/464411—Immunoglobulin superfamily
    • A61K39/464412—CD19 or B4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/4643—Vertebrate antigens
    • A61K39/4644—Cancer antigens
    • A61K39/464402—Receptors, cell surface antigens or cell surface determinants
    • A61K39/464416—Receptors for cytokines
    • A61K39/464417—Receptors for tumor necrosis factors [TNF], e.g. lymphotoxin receptor [LTR], CD30
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/10—Cells modified by introduction of foreign genetic material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K2035/124—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells the cells being hematopoietic, bone marrow derived or blood cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/23—Interleukins [IL]
    • C12N2501/2301—Interleukin-1 (IL-1)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/998—Proteins not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/10041—Use of virus, viral particle or viral elements as a vector
    • C12N2740/10043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/15011—Lentivirus, not HIV, e.g. FIV, SIV
    • C12N2740/15041—Use of virus, viral particle or viral elements as a vector
    • C12N2740/15043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2799/00—Uses of viruses
    • C12N2799/02—Uses of viruses as vector
    • C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2799/00—Uses of viruses
    • C12N2799/02—Uses of viruses as vector
    • C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid
    • C12N2799/027—Uses of viruses as vector for the expression of a heterologous nucleic acid where the vector is derived from a retrovirus
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2810/00—Vectors comprising a targeting moiety
    • C12N2810/50—Vectors comprising as targeting moiety peptide derived from defined protein
    • C12N2810/80—Vectors comprising as targeting moiety peptide derived from defined protein from vertebrates
    • C12N2810/85—Vectors comprising as targeting moiety peptide derived from defined protein from vertebrates mammalian
    • C12N2810/855—Vectors comprising as targeting moiety peptide derived from defined protein from vertebrates mammalian from receptors; from cell surface antigens; from cell surface determinants

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Cell Biology (AREA)
  • Microbiology (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Mycology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hematology (AREA)
  • Virology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Plant Pathology (AREA)
  • Communicable Diseases (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Transplantation (AREA)

Abstract

La invención provee composiciones y métodos para elaborar terapias celulares adoptivas; en modalidades particulares, la invención proporciona métodos para cosechar las poblaciones de células, aislar y activar PBMC, expandir células T y administrar la célula T terapéutica a un sujeto que lo necesita.
MX2016013963A 2014-04-25 2015-04-24 Metodos mejorados para la elaboracion de terapias celulares adoptivas. MX370018B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201461984558P 2014-04-25 2014-04-25
PCT/US2015/027518 WO2015164745A1 (en) 2014-04-25 2015-04-24 Improved methods for manufacturing adoptive cell therapies

Publications (2)

Publication Number Publication Date
MX2016013963A true MX2016013963A (es) 2017-06-12
MX370018B MX370018B (es) 2019-11-28

Family

ID=54333268

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2016013963A MX370018B (es) 2014-04-25 2015-04-24 Metodos mejorados para la elaboracion de terapias celulares adoptivas.
MX2019014009A MX2019014009A (es) 2014-04-25 2016-10-24 Metodos mejorados para la elaboracion de terapias celulares adoptivas.

Family Applications After (1)

Application Number Title Priority Date Filing Date
MX2019014009A MX2019014009A (es) 2014-04-25 2016-10-24 Metodos mejorados para la elaboracion de terapias celulares adoptivas.

Country Status (25)

Country Link
US (1) US20170051252A1 (es)
EP (2) EP3738597A1 (es)
JP (5) JP6817069B2 (es)
KR (3) KR20160141865A (es)
CN (2) CN110819595A (es)
AU (2) AU2015249376C1 (es)
BR (1) BR112016024957A2 (es)
CA (1) CA2946552A1 (es)
CY (1) CY1123142T1 (es)
DK (1) DK3134095T3 (es)
ES (1) ES2800906T3 (es)
HR (1) HRP20200978T1 (es)
HU (1) HUE049514T2 (es)
IL (2) IL248349B (es)
LT (1) LT3134095T (es)
MX (2) MX370018B (es)
NZ (1) NZ725201A (es)
PL (1) PL3134095T3 (es)
PT (1) PT3134095T (es)
RS (1) RS60544B1 (es)
RU (1) RU2741899C2 (es)
SG (2) SG11201608744VA (es)
SI (1) SI3134095T1 (es)
WO (1) WO2015164745A1 (es)
ZA (2) ZA201607175B (es)

Families Citing this family (101)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2817625A2 (en) 2012-02-23 2014-12-31 Stage Cell Therapeutics GmbH Chromatographic isolation of cells and other complex biological materials
EP2971279B1 (en) 2013-03-15 2019-11-13 The Trustees of Princeton University Methods and devices for high throughput purification
US20150064153A1 (en) 2013-03-15 2015-03-05 The Trustees Of Princeton University High efficiency microfluidic purification of stem cells to improve transplants
WO2014145152A2 (en) 2013-03-15 2014-09-18 Gpb Scientific, Llc On-chip microfluidic processing of particles
PL3132247T3 (pl) 2014-04-16 2022-01-03 Juno Therapeutics Gmbh Sposoby, zestawy i urządzenie do namnażania populacji komórek
KR102447958B1 (ko) 2014-04-23 2022-09-27 주노 쎄러퓨티크스 인코퍼레이티드 입양 치료용 면역 세포 집단의 단리, 배양 및 유전자 조작 방법
LT3134432T (lt) 2014-04-25 2020-04-10 Bluebird Bio, Inc. Mnd promotorius chimerinių antigenų receptoriams
SG10202108458XA (en) 2014-06-06 2021-09-29 2Seventy Bio Inc Improved t cell compositions
AU2015292590B2 (en) * 2014-07-24 2020-01-16 2Seventy Bio, Inc. BCMA chimeric antigen receptors
EP3230441A4 (en) 2014-12-12 2018-10-03 Voyager Therapeutics, Inc. Compositions and methods for the production of scaav
CN112358551B (zh) 2014-12-12 2024-02-02 2赛文缇生物公司 Bcma嵌合抗原受体
EP4036109A3 (en) 2014-12-29 2022-10-12 Novartis AG Methods of making chimeric antigen receptor-expressing cells
ES2948133T3 (es) 2015-04-17 2023-08-31 Novartis Ag Métodos para mejorar la eficacia y expansión de células que expresan un receptor de antígeno quimérico
PL3298033T5 (pl) 2015-05-18 2023-10-30 TCR2 Therapeutics Inc. Kompozycje i zastosowania medyczne do reprogramowania TCR z zastosowaniem białek fuzyjnych
FR3038324B1 (fr) 2015-06-30 2020-10-30 Lab Francais Du Fractionnement Procede de cryoconservation de cellules a visee therapeutique
AR105433A1 (es) 2015-07-21 2017-10-04 Novartis Ag Métodos para mejorar la eficacia y expansión de las células inmunes
US10976232B2 (en) 2015-08-24 2021-04-13 Gpb Scientific, Inc. Methods and devices for multi-step cell purification and concentration
TWI630934B (zh) * 2015-10-14 2018-08-01 瑞典商神經毫微股份有限公司 移植醫藥設備到神經組織中的方法以及設備
AU2016341527B2 (en) 2015-10-22 2023-04-27 Juno Therapeutics Gmbh Methods, kits, agents and apparatuses for transduction
MA45489A (fr) 2015-10-22 2018-08-29 Juno Therapeutics Gmbh Procédés de culture de cellules, kits et appareil associés
SG11201803098VA (en) 2015-10-30 2018-05-30 Nbe Therapeutics Ag Anti-ror1 antibodies
JP2018536436A (ja) 2015-12-04 2018-12-13 ノバルティス アーゲー 免疫腫瘍学のための組成物および方法
US11479755B2 (en) 2015-12-07 2022-10-25 2Seventy Bio, Inc. T cell compositions
SG11201805449PA (en) * 2015-12-28 2018-07-30 Novartis Ag Methods of making chimeric antigen receptor -expressing cells
TW201736399A (zh) 2015-12-31 2017-10-16 財團法人生物技術開發中心 抗vegfr抗體及其應用
CA3011815A1 (en) 2016-01-20 2017-07-27 The Scripps Research Institute Ror1 antibody compositions and related methods
CN109415687A (zh) * 2016-04-07 2019-03-01 蓝鸟生物公司 嵌合抗原受体t细胞组合物
WO2017176932A1 (en) * 2016-04-08 2017-10-12 Emory University Methods of treating cancer and infectious diseases using cell based therapies
CN105907790A (zh) * 2016-06-21 2016-08-31 林志国 特异性识别EGFRvⅢ的含CD70嵌合抗原受体修饰T细胞的制备方法
CN109715668A (zh) 2016-08-02 2019-05-03 T细胞受体治疗公司 用于使用融合蛋白进行tcr重编程的组合物和方法
ES2875959T3 (es) 2016-10-07 2021-11-11 Tcr2 Therapeutics Inc Composiciones y métodos para reprogramación de receptores de linfocitos T mediante el uso de proteínas de fusión
WO2018075940A1 (en) * 2016-10-21 2018-04-26 Georgia Tech Research Corporation Methods and systems for t cell expansion
AU2017350739B2 (en) * 2016-10-24 2023-03-16 Gpb Scientific, Inc. Deterministic lateral displacement in the preparation of cells and compositions for therapeutic uses
US11851491B2 (en) 2016-11-22 2023-12-26 TCR2 Therapeutics Inc. Compositions and methods for TCR reprogramming using fusion proteins
EP4035659A1 (en) 2016-11-29 2022-08-03 PureTech LYT, Inc. Exosomes for delivery of therapeutic agents
US20190367876A1 (en) * 2017-01-18 2019-12-05 F1 Oncology, Inc. Methods of transducing and expanding immune cells and uses thereof
JP2020506700A (ja) 2017-01-31 2020-03-05 ノバルティス アーゲー 多重特異性を有するキメラｔ細胞受容体タンパク質を用いた癌の治療
EA201992232A1 (ru) 2017-03-22 2020-05-14 Новартис Аг Композиции и способы для иммуноонкологии
CN110678190A (zh) * 2017-03-28 2020-01-10 宾夕法尼亚大学董事会 保护移植的组织免受排斥的方法
US20200055948A1 (en) 2017-04-28 2020-02-20 Novartis Ag Cells expressing a bcma-targeting chimeric antigen receptor, and combination therapy with a gamma secretase inhibitor
WO2018201051A1 (en) 2017-04-28 2018-11-01 Novartis Ag Bcma-targeting agent, and combination therapy with a gamma secretase inhibitor
CN109134660B (zh) * 2017-06-16 2022-07-01 上海恒润达生生物科技股份有限公司 靶向Mesothelin的嵌合抗原受体并联合表达抗PD1抗体的方法及其用途
CN107236762A (zh) * 2017-06-19 2017-10-10 河北浓孚雨生物科技有限公司 一种微环dna转染t细胞制备临床级car‑t细胞制剂的方法
EP3648757A4 (en) * 2017-07-03 2020-11-25 Development Center for Biotechnology ANTI-VEGFR ANTIBODIES AND USES THEREOF
AU2018315127B2 (en) 2017-08-07 2021-12-23 Nbe-Therapeutics Ag Anthracycline-based antibody drug conjugates having high in vivo tolerability
KR20200054178A (ko) 2017-08-09 2020-05-19 주노 쎄러퓨티크스 인코퍼레이티드 유전자 조작된 세포 조성물 및 관련 조성물의 제조 방법
CN114958772A (zh) 2017-09-01 2022-08-30 隆萨沃克斯维尔股份有限公司 端到端细胞治疗自动化
EP3675876A4 (en) * 2017-09-01 2021-06-02 GPB Scientific, Inc. PROCESSES FOR PREPARING THERAPEUTICALLY ACTIVE CELLS USING MICROFLUIDICS
JP2021501570A (ja) 2017-10-18 2021-01-21 ノバルティス アーゲー 選択的タンパク質分解のための組成物及び方法
CN107893055B (zh) * 2017-11-03 2020-07-17 深圳市默赛尔生物医学科技发展有限公司 一种特异性嵌合抗原受体基因修饰的自然杀伤细胞及其制备方法和用途
MA50571A (fr) * 2017-11-10 2020-09-16 Juno Therapeutics Inc Réservoirs cryogéniques à système fermé
CN109776671B (zh) * 2017-11-14 2022-05-27 杭州康万达医药科技有限公司 分离的t细胞受体、其修饰的细胞、编码核酸、表达载体、制备方法、药物组合物和应用
AU2018369883A1 (en) 2017-11-15 2020-05-28 Novartis Ag BCMA-targeting chimeric antigen receptor, CD19-targeting chimeric antigen receptor, and combination therapies
JP2021509009A (ja) 2017-11-30 2021-03-18 ノバルティス アーゲー Ｂｃｍａターゲティングキメラ抗原受容体及びその使用
US20200384025A1 (en) * 2017-12-08 2020-12-10 Juno Therapeutics, Inc. Process for producing a composition of engineered t cells
CN109609533B (zh) * 2017-12-27 2020-07-10 赛德特生物科技开发有限公司 基于人源化cd276抗体的car慢病毒表达载体构建及其应用
WO2019136432A1 (en) 2018-01-08 2019-07-11 Novartis Ag Immune-enhancing rnas for combination with chimeric antigen receptor therapy
CN112125976B (zh) * 2018-01-26 2022-06-03 重庆精准生物技术有限公司 改造的铰链及其在构建car骨架中的应用
AU2019215031A1 (en) 2018-01-31 2020-08-20 Novartis Ag Combination therapy using a chimeric antigen receptor
DE102018108996B4 (de) 2018-02-09 2021-10-21 Immatics US, Inc. Verfahren zur Herstellung autologer T-Zellen
MX2020008327A (es) * 2018-02-09 2020-10-28 Immatics Us Inc Metodos para preparar celulas t.
US20200399383A1 (en) 2018-02-13 2020-12-24 Novartis Ag Chimeric antigen receptor therapy in combination with il-15r and il15
CN110272481A (zh) * 2018-03-14 2019-09-24 中国科学院广州生物医药与健康研究院 识别mage1抗原短肽的t细胞受体
WO2019178314A1 (en) * 2018-03-14 2019-09-19 Thermogenesis Corporation Buoyancy-activated cell sorting (bacs)-compatible activation/transduction systems and methods
DE102018108612A1 (de) * 2018-03-21 2019-09-26 Immatics US, Inc. Verfahren zur erhöhung der persistenz von adoptiv infundierten t-zellen
AU2019257749A1 (en) 2018-04-27 2020-10-22 Iovance Biotherapeutics, Inc. Closed process for expansion and gene editing of tumor infiltrating lymphocytes and uses of same in immunotherapy
US20210087530A1 (en) * 2018-05-08 2021-03-25 Life Technologies Corporation Compositions and methods for culturing and expanding cells
CN108929862A (zh) * 2018-08-01 2018-12-04 上海市第人民医院 一种恶性肿瘤肺转移伴恶性胸腔积液的t细胞制备与扩增方法及其应用
CA3109959A1 (en) 2018-08-31 2020-03-05 Novartis Ag Methods of making chimeric antigen receptor-expressing cells
WO2020047449A2 (en) 2018-08-31 2020-03-05 Novartis Ag Methods of making chimeric antigen receptor-expressing cells
TW202027761A (zh) 2018-09-21 2020-08-01 美商柏克萊燈光有限公司 功能化孔盤、其製備方法及用途
KR20210095157A (ko) 2018-11-08 2021-07-30 넥스이뮨, 인크. 개선된 표현형 속성을 갖는 t 세포 조성물
SG11202104994PA (en) * 2018-11-16 2021-06-29 Celgene Corp Improved t cell manufacturing process
EP3883955A1 (en) * 2018-11-19 2021-09-29 Board of Regents, The University of Texas System A modular, polycistronic vector for car and tcr transduction
WO2020124231A1 (en) 2018-12-21 2020-06-25 Octane Biotech Inc. Carousel for modular biologic production units
WO2020132177A1 (en) 2018-12-21 2020-06-25 Lonza Walkersville, Inc. Automated production of viral vectors
JP7536026B2 (ja) 2019-02-08 2024-08-19 ロンザ ウォーカーズヴィル，インコーポレーテッド 自動化バイオリアクターにおける使用のための細胞濃縮方法および細胞濃縮デバイス
CA3126087A1 (en) 2019-02-25 2020-09-03 Novartis Ag Mesoporous silica particles compositions for viral delivery
US20200297768A1 (en) * 2019-03-19 2020-09-24 Immatics US, Inc. Cd28 t cell cultures, compositions, and methods of using thereof
DE102019108125B4 (de) 2019-03-28 2022-02-03 Immatics US, Inc. Cd28 t-zellkulturen, zusammensetzungen und verfahren zu deren verwendung
EP3942025A1 (en) 2019-03-21 2022-01-26 Novartis AG Car-t cell therapies with enhanced efficacy
EP3945815A4 (en) * 2019-04-03 2023-04-19 Akron Biotechnology, LLC CRYOPRESERVATION AND CELL CULTURE MEDIA
CN113766919A (zh) * 2019-04-05 2021-12-07 2赛文缇生物公司 制造抗bcma car t细胞
WO2020210678A1 (en) 2019-04-12 2020-10-15 Novartis Ag Methods of making chimeric antigen receptor-expressing cells
US20220251152A1 (en) 2019-04-24 2022-08-11 Novartis Ag Compositions and methods for selective protein degradation
MX2021014304A (es) * 2019-05-23 2022-02-21 Massachusetts Inst Technology Descubrimiento de ligandos y suministro de genes a traves de la presentacion en superficie retroviral.
EP4021180A4 (en) * 2019-08-29 2023-11-08 Board of Regents, The University of Texas System CELL CRYOPRESERVATION MEDIUM
US12016883B2 (en) 2019-09-26 2024-06-25 Nantbio, Inc. Primary T-cell expansion
CN110747166B (zh) * 2019-10-11 2021-07-09 厦门大学 一种外周血t细胞的体外扩增培养方法
TW202134264A (zh) 2019-11-26 2021-09-16 瑞士商諾華公司 嵌合抗原受體及其用途
CN115175695A (zh) 2020-02-27 2022-10-11 诺华股份有限公司 制备表达嵌合抗原受体的细胞的方法
EP4110377A2 (en) 2020-02-27 2023-01-04 Novartis AG Methods of making chimeric antigen receptor-expressing cells
US20210335467A1 (en) * 2020-04-22 2021-10-28 Iovance Biotherapeutics, Inc. Systems and methods for coordinating manufacturing of cells for patient-specific immunotherapy
US20230332104A1 (en) 2020-06-11 2023-10-19 Novartis Ag Zbtb32 inhibitors and uses thereof
CA3188978A1 (en) 2020-08-21 2022-02-24 Sandeep Tharian Koshy Compositions and methods for in vivo generation of car expressing cells
AR125468A1 (es) 2021-04-27 2023-07-19 Novartis Ag Sistema de producción de vectores virales
EP4388000A1 (en) 2021-08-20 2024-06-26 Novartis AG Methods of making chimeric antigen receptor?expressing cells
CN114317435B (zh) * 2021-12-30 2024-02-27 杭州芯递力生物科技有限公司 一种获得抗原特异性t细胞的方法
WO2023230512A1 (en) 2022-05-26 2023-11-30 2Seventy Bio, Inc. Compositions for maintaining lentiviral vector and uses thereof
WO2024089639A1 (en) 2022-10-26 2024-05-02 Novartis Ag Lentiviral formulations
WO2024170791A1 (en) * 2023-02-17 2024-08-22 Lumicks Ca Holding B.V. Means and methods for determining cellular avidity of primary t cells and target cells

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4873192A (en) 1987-02-17 1989-10-10 The United States Of America As Represented By The Department Of Health And Human Services Process for site specific mutagenesis without phenotypic selection
US6905680B2 (en) * 1988-11-23 2005-06-14 Genetics Institute, Inc. Methods of treating HIV infected subjects
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
DE3920358A1 (de) 1989-06-22 1991-01-17 Behringwerke Ag Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung
US5283173A (en) 1990-01-24 1994-02-01 The Research Foundation Of State University Of New York System to detect protein-protein interactions
GB9114948D0 (en) 1991-07-11 1991-08-28 Pfizer Ltd Process for preparing sertraline intermediates
US6005079A (en) 1992-08-21 1999-12-21 Vrije Universiteit Brussels Immunoglobulins devoid of light chains
DK1589107T3 (da) 1992-08-21 2010-04-26 Univ Bruxelles Immonuglobuliner uden lette kæder
AU6796094A (en) 1993-04-29 1994-11-21 Raymond Hamers Production of antibodies or (functionalized) fragments thereof derived from heavy chain immunoglobulins of (camelidae)
IL125884A0 (en) * 1996-03-04 1999-04-11 Targeted Genetics Corp Modified rapid expansion methods ("modified-rem") for in vitro propagation of t lymphocytes
FR2777909B1 (fr) 1998-04-24 2002-08-02 Pasteur Institut Utilisation de sequences d'adn de structure triplex pour le tranfert de sequences de nucleotides dans des cellules, vecteurs recombinants contenant ces sequences triplex
ATE373078T1 (de) * 2000-02-24 2007-09-15 Xcyte Therapies Inc Gleichzeitige stimulation und konzentration von zellen
DE60234824D1 (de) 2001-05-01 2010-02-04 Ca Nat Research Council Induzierbares expressionssystem in eukaryotischen zellen
US7638325B2 (en) 2002-01-03 2009-12-29 The Trustees Of The University Of Pennsylvania Activation and expansion of T-cells using an engineered multivalent signaling platform
GB0224442D0 (en) * 2002-10-21 2002-11-27 Molmed Spa A delivery system
JP2006524991A (ja) * 2003-05-08 2006-11-09 エクサイト セラピーズ インコーポレーティッド 抗原特異的ｔ細胞の作製および単離の方法
CA2568344C (en) * 2004-05-27 2016-01-19 The Trustees Of The University Of Pennsylvania Novel artificial antigen presenting cells and uses therefor
AU2006251621A1 (en) * 2005-05-20 2006-11-30 Virxsys Corporation Transduction of primary cells
EP2155873B1 (en) * 2007-05-23 2016-11-09 Sangamo BioSciences, Inc. Methods and compositions for increased transgene expression
TR201904484T4 (tr) 2009-11-03 2019-05-21 Hope City Transdüse T hücre seçimine yönelik kesik epiderimal büyüme faktörü reseptörü (EGFRt).
DK2649086T3 (en) 2010-12-09 2017-09-18 Univ Pennsylvania USING CHEMICAL ANTIGEN RECEPTOR-MODIFIED T-CELLS TO TREAT CANCER
EP2697367B1 (en) * 2011-04-13 2018-12-19 Immunicum AB Method for proliferation of antigen-specific t cells
BR112014020499A2 (pt) * 2012-02-22 2019-09-24 Univ Pennsylvania sequência de ácido nucleico isolada, célula - t, vetor, e, população persistente de células - t
KR20220029757A (ko) * 2012-04-11 2022-03-08 더 유나이티드 스테이츠 오브 어메리카, 애즈 리프리젠티드 바이 더 세크러테리, 디파트먼트 오브 헬쓰 앤드 휴먼 서비씨즈 B-세포 성숙 항원을 표적화하는 키메라 항원 수용체
US20130280220A1 (en) 2012-04-20 2013-10-24 Nabil Ahmed Chimeric antigen receptor for bispecific activation and targeting of t lymphocytes
PT2893004T (pt) * 2012-09-04 2019-01-21 Cellectis Recetor de antígeno quimérico de cadeia múltipla e utilizações do mesmo
EP2711418B1 (en) 2012-09-25 2017-08-23 Miltenyi Biotec GmbH Method for polyclonal stimulation of T cells by flexible nanomatrices
US9365641B2 (en) * 2012-10-01 2016-06-14 The Trustees Of The University Of Pennsylvania Compositions and methods for targeting stromal cells for the treatment of cancer
EP2906684B8 (en) * 2012-10-10 2020-09-02 Sangamo Therapeutics, Inc. T cell modifying compounds and uses thereof
WO2014099671A1 (en) 2012-12-20 2014-06-26 Bluebird Bio, Inc. Chimeric antigen receptors and immune cells targeting b cell malignancies

Also Published As

Publication number Publication date
BR112016024957A2 (pt) 2017-10-24
JP7536808B2 (ja) 2024-08-20
KR20180105733A (ko) 2018-09-28
PT3134095T (pt) 2020-07-02
JP2020015767A (ja) 2020-01-30
RU2016145968A3 (es) 2018-11-13
CN106456670B (zh) 2020-01-07
NZ725201A (en) 2018-05-25
IL276593B (en) 2021-10-31
JP7012056B2 (ja) 2022-02-10
CA2946552A1 (en) 2015-10-29
JP2017513891A (ja) 2017-06-01
JP2022040287A (ja) 2022-03-10
IL248349A0 (en) 2016-11-30
AU2015249376C1 (en) 2019-10-31
EP3134095A1 (en) 2017-03-01
ES2800906T3 (es) 2021-01-05
EP3134095A4 (en) 2017-09-20
EP3738597A1 (en) 2020-11-18
ZA201902286B (en) 2022-08-31
IL248349B (en) 2020-08-31
DK3134095T3 (da) 2020-06-29
JP6817069B2 (ja) 2021-01-20
LT3134095T (lt) 2020-06-10
AU2018203687C1 (en) 2022-01-13
RS60544B1 (sr) 2020-08-31
KR20190066089A (ko) 2019-06-12
PL3134095T3 (pl) 2020-10-19
US20170051252A1 (en) 2017-02-23
KR101988614B1 (ko) 2019-06-12
RU2741899C2 (ru) 2021-01-29
JP2018087254A (ja) 2018-06-07
SI3134095T1 (sl) 2020-08-31
WO2015164745A1 (en) 2015-10-29
KR20160141865A (ko) 2016-12-09
JP2024086948A (ja) 2024-06-28
HRP20200978T1 (hr) 2020-10-16
SG10201808258SA (en) 2018-10-30
CN110819595A (zh) 2020-02-21
AU2015249376A1 (en) 2016-11-03
CN106456670A (zh) 2017-02-22
IL276593A (en) 2020-09-30
CY1123142T1 (el) 2021-10-29
AU2015249376B2 (en) 2018-03-08
MX370018B (es) 2019-11-28
KR102161927B1 (ko) 2020-10-06
SG11201608744VA (en) 2016-11-29
AU2018203687B2 (en) 2019-03-21
EP3134095B1 (en) 2020-04-22
MX2019014009A (es) 2020-02-05
HUE049514T2 (hu) 2020-09-28
AU2018203687A1 (en) 2018-06-21
RU2016145968A (ru) 2018-05-28
ZA201607175B (en) 2022-08-31

Similar Documents

Publication Publication Date Title
MX2019014009A (es) Metodos mejorados para la elaboracion de terapias celulares adoptivas.
IL280743B (en) Methods for enriching and producing immune cell populations for stress treatment
IL290744A (en) Methods for the production of autologous t cells used in the treatment of b-cell malignancies and other types of cancer and preparations thereof
HK1255161A1 (zh) 用於過繼性細胞治療的工程細胞
HK1244826A1 (zh) 用於過繼細胞治療的方法和組合物
NZ726989A (en) Improved t cell compositions
EP3619234A4 (en) COMPOSITIONS AND METHODS FOR ADOPTIVE CELL THERAPIES
IL250072A0 (en) Transgenic cells for stress cell therapy
EP4374863A3 (en) Methods for generating stem cell-derived beta cells and uses thereof
TR201907106T4 (tr) Bir transplant alıcısında immünosüpresif terapileri izleme yöntemleri.
EP3370743A4 (en) METHODS OF PREPARING LYMPHOCYTES FOR ADOPTIVE TRANSFER THERAPY OF T-CELLS
MX2020000621A (es) Composiciones para usarse en inmunomodulacion.
EP3426263A4 (en) METHOD AND ARTICLE FOR THE DELIVERY OF LIVABLE CELLS IN SOLID TISSUE
SG10202104804PA (en) Methods and compositions for dosing in adoptive cell therapy
MY185016A (en) Progenitor cells of mesodermal lineage
EP4292600A3 (en) Photoreceptors and photoreceptor progenitors produced from pluripotent stem cells
MX2015009106A (es) Composiciones de solución sólida y su uso en el tratamiento del dolor intenso.
MY181994A (en) Immuno-modulatory progenitor (imp) cell
IN2015DN00143A (es)
MX365403B (es) Peptidos y metodos para usarlos.
EP2558124A4 (en) POLYSACCHARID COMPOSITIONS AND METHOD FOR USE THEREOF FOR THE TREATMENT AND PREVENTION OF DISEASES ASSOCIATED WITH PRECURSOR CELL MOBILIZATION
WO2014134084A3 (en) Phf20 and jmjd3 compositions and methods of use in cancer immunotherapy
EP3224350A4 (en) Modulation of sh2b3 to improve red blood cell production from stem cells and/or progenitor cells
EP4295914A3 (en) Genetically-engineered drug resistant t cells and methods of using the same
MX363385B (es) Métodos para el tratamiento de enfermedad de células falciformes y otras condiciones inflamatorias.

Legal Events

Date Code Title Description
FG Grant or registration